GPhA commends IGBA for persuading WHO evaluation of BQ impact

The Generic Pharmaceutical Association (GPhA) and its Biosimilars Council has released a statement from its President and CEO, Chip Davis, commending the International Generic and Biosimilar Medicines Association (IGBA) for persuading the World Health Organization (WHO) to carry out an evaluation of the global impact for the voluntary biologic qualifier (BQ) proposal for the quality, safety and access to biologic products. Read More »